TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05223855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic hydrotherapy treatment
Description: Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010).
Study: NCT05021367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3823 tablets
Description: TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
Study: NCT04721249

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-serine
Description: Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
Study: NCT05542004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
Study: NCT05272254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine + FV
Description: applied to children's teeth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo +FV
Description: applied to children's teeth
Study: NCT05763732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait.
Study: NCT06080802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
Study: NCT04819204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
Study: NCT04937309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive auricular vagal stimulation
Description: Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
Study: NCT00824759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pure oxygen breathing versus air
Description: one group will breath pure oxygen; the other will breath air

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pure oxygen breathing versus air
Description: one group will breath pure oxygen; the other will breath air
Study: NCT06410833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab every four weeks
Study: NCT05392361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin (neurontin® capsule 300mg) treatment
Description: Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen (baclofen Tab. 10mg) treatment
Description: Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
Study: NCT05162495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStation T101 and TeraTube
Description: Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStation T101 and TeraTube
Description: Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
Study: NCT05948800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with seawater isotonic solution
Description: Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
Study: NCT05652361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional visualisation of surgical assistance during surgery
Description: Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
Study: NCT05406882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules
Description: Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
Study: NCT04937309

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: usual medical treatment
Description: Standard anti emetic treatments to prevent emesis due to chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: usual medical treatment
Description: Standard anti emetic treatments to prevent emesis due to chemotherapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
Study: NCT05689424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HDV-Insulin Lispro
Description: The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDV-Insulin Lispro
Description: The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
Study: NCT05352958

Intervention type: PROCEDURE
Intervention: Diaphragmatic ultrasound
Description: duration 15 minutes, performed at M0, M3, M6 and M9
Study: NCT05689424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDV-Insulin Lispro
Description: The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDV-Insulin Lispro
Description: The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
Study: NCT05352958

Intervention type: OTHER
Intervention: Electro-physiological exploration of the diaphragm
Description: duration between 30 and 60 minutes performed at M0
Study: NCT06252831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS-Probionorm
Description: Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol.
Study: NCT05217017

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FACS
Description: Diagnostic Test: Assessment of disability and behavior (by questionnaires)
Study: NCT05221658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+HLX10+ Cisplatin+5-FU
Description: HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 1000mg iv Q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 1000mg iv Q2w
Study: NCT05686668

Intervention type: OTHER
Intervention: assessment by scales
Description: Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
Study: NCT05768477

Intervention type: OTHER
Intervention: Consultation
Description: Consultation with the pain specialist, which might entail prescription of medication of vitamins.
Study: NCT06585137

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Mind-Body Awareness Program
Description: The program will be developed with the opinions of experts in line with the literature. It will include a nursing approach based on Meleis transition theory, education, mind-body awareness practices, and messages specific to the health of women. Participants will receive training consisting of 6 modules for an average of 2 weeks. Participants will be asked to complete the first post-test one day after the ovum pick-up (OPU) procedure, corresponding to an average of 8-12 days after ovulation induction. Afterward, pranayama breathing and autogenic relaxation exercises will be applied weekly via the interactive online system after the OPU procedure. Then, the second post-test will be applied in the 3rd month, and the third post-test will be applied in the 6th month.
Study: NCT06386354

Intervention type: DIAGNOSTIC_TEST
Intervention: Train-of-four
Description: Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
Study: NCT06585163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Hydrocodone bitartrate oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Hydrocodone bitartrate oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxapram Hydrochloride
Description: Doxapram hydrocholoride oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxapram Hydrochloride
Description: Doxapram hydrocholoride oral suspension
Study: NCT05768477

Intervention type: PROCEDURE
Intervention: Interventions
Description: Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation

Intervention type: DRUG
Intervention: Baxter therapy
Description: Ketamine or Linisol baxter therapy
Study: NCT05223764

Intervention type: OTHER
Intervention: Follow up survey
Description: phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
Study: NCT05821998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic block technique
Description: Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Designed chest physical therapy program
Description: Percussion, vibration and modified postural drainage
Study: NCT05768477

Intervention type: BEHAVIORAL
Intervention: Interdisciplinary therapy
Description: Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
Study: NCT06499532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique
Description: The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
Study: NCT05718232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
Study: NCT05169788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teen On-line Problem Solving
Description: The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teen On-line Problem Solving
Description: The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
Study: NCT04693390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Application of acupuncture
Study: NCT05888285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina bale block and pulsed radiofrequency
Description: The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
Study: NCT02871726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUS-Robot
Description: A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRUS biopsy
Description: Uronav for prostate biopsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRUS biopsy
Description: Uronav for prostate biopsy.
Study: NCT05749562

Intervention type: DEVICE
Intervention: Cheneau-Toulouse-Munster brace
Description: Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
Study: NCT05619991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group watching video
Description: The video will include preparation for the surgery, the operating room environment and the post-operative process.

Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled training group
Description: The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
Study: NCT05244954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
Study: NCT05830422

Intervention type: OTHER
Intervention: nothing
Description: Follow-up observation was conducted without any intervention in an outpatient setting.
Study: NCT05396573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3013
Description: A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: A single dose of 30 μg/0.3 mL